<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35586583</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2778-2034</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Medecine tropicale et sante internationale</Title><ISOAbbreviation>Med Trop Sante Int</ISOAbbreviation></Journal><ArticleTitle>[Discovery of Foci of Type-2 Poliovirus Derived from Oral Polio Vaccine in Central African Republic in 2019].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">mtsibulletin.2021.114</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.48327/mtsibulletin.2021.114</ELocationID><Abstract><AbstractText Label="OBJECTIVE">In 2019, the Central African Republic identified foci of circulating vaccine-derived poliovirus 2 (PVDV2c). The objective of this work is to describe the vaccination status of children paralyzed by PVDV2c and their contacts and to assess the circulation of this strain in these contacts.</AbstractText><AbstractText Label="PATIENTS AND METHOD">The study population of this retrospective survey consists of children with acute flaccid paralysis (AFP) and their contacts. We included paralyzed children whose sequencing results showed the presence of PVDV2c.</AbstractText><AbstractText Label="RESULTS">A total of 21 children paralyzed by PVDVc and 64 contacts were enrolled in the survey. Fourteen out of 21 children who are paralyzed (66%) received at least one dose of bivalent oral polio vaccine (OPV) compared to 36 out of 64 contacts (57%, non-significant difference). Of the vaccinated patients, 7 had received less than three doses. For the injectable polio vaccine (IPV), vaccination coverage for both patients and contacts was 33%.The proportion of children who received both doses of OPV and IPV was 33% among patients and 25% in contacts. Contacts with VDPV2 were vaccinated with OPV and IPV, respectively 55 and 27%. VDPV2 and Sabin 2 were also found in contact stools, 34% and 9% respectively.</AbstractText><AbstractText Label="CONCLUSION">The absence or inadequacy of IPV vaccination has a serious impact on children by the occurrence of virus derived from the vaccine responsible for life-old paralysis. Protecting children from poliomyelitis requires a combination of a good cold chain, multiple doses and adherence to the vaccine schedule.</AbstractText><CopyrightInformation>Copyright © 2021 SFMTSI.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalthan</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ministère de la santé et de la population, direction de la surveillance épidémiologique et de gestion d'urgence en santé publique, République centrafricaine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouandjika-Vasilache</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Bangui, laboratoire régional de référence OMS pour la poliomyélite en Afrique, République centrafricaine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mbailao</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ministère de la santé et de la population, direction générale de l'épidémiologie et de lutte contre les maladies, République centrafricaine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doté</LastName><ForeName>J W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Bangui, laboratoire régional de référence OMS pour la poliomyélite en Afrique, République centrafricaine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kossone</LastName><ForeName>M N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Ministère de la santé et de la population, district sanitaire de Bambari, République centrafricaine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gbangai</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ministère de la santé et de la population, service de la vaccination, République centrafricaine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Découverte de Foyers de Poliovirus de Type-2 Dérivé du Vaccin Antipoliomyélitique Oral en République Centrafricaine en 2019.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Med Trop Sante Int</MedlineTA><NlmUniqueID>9918227363206676</NlmUniqueID><ISSNLinking>2778-2034</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002488" MajorTopicYN="N" Type="Geographic">Central African Republic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="N">Poliovirus Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="OBJECTIF">En 2019, la République centrafricaine a découvert des foyers de poliovirus de type 2 dérivé vaccinal circulant (PVDV2c). L'objectif de ce travail est de décrire l'état vaccinal des enfants paralysés par le PVDV2c et leurs contacts et d'évaluer la circulation de cette souche chez ces contacts.</AbstractText><AbstractText Label="PATIENTS ET MÉTHODE">Il s'agit d'une étude rétrospective et descriptive. La population d'étude est constituée des enfants atteints de paralysie flasque aiguë (PFA) et de leurs contacts. Nous avons inclus les enfants paralysés dont les résultats de séquençage ont montré la présence du PVDV2c.</AbstractText><AbstractText Label="RÉSULTATS">Au total, 21 enfants paralysés par le PVDVc et 64 contacts ont été enrôlés dans cette étude. Quatorze enfants paralysés sur 21 (66%) avaient reçu au moins une dose de vaccin antipoliomyélitique oral (VPO) bivalent contre 36 sur 64 (57%) chez les contacts (différence non significative). Parmi les malades vaccinés, 7 avaient reçu moins de trois doses. Pour le vaccin polio injectable (VPI), la couverture vaccinale chez les malades comme pour les contacts était de 33%. La proportion des enfants ayant reçu à la fois des doses de VPO et de VPI était de 33% chez les malades et 25% chez les contacts. Les contacts porteurs de VDPV2 ont été vaccinés par le VPO et VPI, respectivement 55% et 27%. Le VDPV2 et le Sabin 2 ont également été trouvés dans les selles des contacts, respectivement 34% et 9%.</AbstractText><AbstractText Label="CONCLUSION">L'insuffisance de vaccination en VPO et VPI pendant plusieurs années a des conséquences graves par la survenue de virus dérivé du vaccin et responsable de paralysie à vie. Pour arrêter l'épidémie de VDPVc, il faut renforcer la couverture vaccinale par une campagne de masse couvrant tous les districts en même temps.</AbstractText><CopyrightInformation>Copyright © 2021 SFMTSI.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute flaccid paralysis</Keyword><Keyword MajorTopicYN="N">Bambari</Keyword><Keyword MajorTopicYN="N">Bangassou</Keyword><Keyword MajorTopicYN="N">Bangui</Keyword><Keyword MajorTopicYN="N">Berberati</Keyword><Keyword MajorTopicYN="N">Bimbo</Keyword><Keyword MajorTopicYN="N">Bocaranga</Keyword><Keyword MajorTopicYN="N">Central African Republic</Keyword><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Injectable polio vaccine</Keyword><Keyword MajorTopicYN="N">Kemo</Keyword><Keyword MajorTopicYN="N">Mbaiki</Keyword><Keyword MajorTopicYN="N">Nola</Keyword><Keyword MajorTopicYN="N">Oral polio vaccine</Keyword><Keyword MajorTopicYN="N">PVDVc2</Keyword><Keyword MajorTopicYN="N">Subsaharan Africa</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Vaccination coverage</Keyword></KeywordList><CoiStatement>Les auteurs ne déclarent aucun conflit d'intérêt.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>2</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35586583</ArticleId><ArticleId IdType="pmc">PMC9022749</ArticleId><ArticleId IdType="doi">10.48327/mtsibulletin.2021.114</ArticleId><ArticleId IdType="pii">mtsibulletin.2021.114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bazira L, Coulibaly T, Mayenga M, Ncharre C, Yogolelo R, Mbule A, Moudzeo H, Lwamba P, Mulumba AW, Cabore J. Épidémie de poliovirus circulants dérivés de souches vaccinales de type 2 en République démocratique du Congo de 2011 à 2012. Bull Soc Pathol Exot. 2015 Oct;108(4):235–41. doi: 10.1007/s13149-015-0447-4. Epub 2015 Aug 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13149-015-0447-4</ArticleId><ArticleId IdType="pubmed">26288132</ArticleId></ArticleIdList></Reference><Reference><Citation>Delpeyroux F, Colbère-Garapin F, Razafindratsimandresy R, Sadeuh-Mba S, Joffret ML, Rousset D, Blondel B. Éradication de la poliomyélite et émergence de poliovirus pathogènes dérivés du vaccin - De Madagascar au Cameroun. Med Sci (Paris) 2013 Nov;29(11):1034–41. doi: 10.1051/medsci/20132911021. Epub 2013 Nov 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/medsci/20132911021</ArticleId><ArticleId IdType="pubmed">24280508</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol. 1999 Nov 15;150(10):1001–21. doi: 10.1093/oxfordjournals.aje.a009924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a009924</ArticleId><ArticleId IdType="pubmed">10568615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumede N, Lentsoane O, Burns CC, Pallansch M, de Gourville E, Yogolelo R, Muyembe-Tamfum JJ, Puren A, Schoub BD, Venter M. Emergence of vaccine-derived polioviruses, Democratic Republic of Congo, 2004-2011. Emerg Infect Dis. 2013 Oct;19(10):1583–9. doi: 10.3201/eid1910.130028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1910.130028</ArticleId><ArticleId IdType="pmc">PMC3810735</ArticleId><ArticleId IdType="pubmed">24047933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Nottay BK. Molecular epidemiology of polioviruses. Rev Infect Dis. 1984 May-Jun;6(Suppl 2):S499–S504. doi: 10.1093/clinids/6.supplement_2.s499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/6.supplement_2.s499</ArticleId><ArticleId IdType="pubmed">6330846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ. 2004 Jan;82(1):16–23. Epub 2004 Feb 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585883</ArticleId><ArticleId IdType="pubmed">15106296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mala Rakoto Andrianarivelo. Emergence de souches de poliovirus recombinantes dérivées du vaccin polio oral à Madagascar.  Thèse de doctorat en Sciences. Génétique, Immunologie, Infectiologie et développement. 2005.   https://www.theses.fr/2005PA05N03S Consulté le 12 avril 2020.</Citation></Reference><Reference><Citation>OMS.  Questions fréquentes sur la poliomyélite.   https://www.who.int/topics/poliomyelitis/faq/fr/ Consulté le 26 avril 2020.</Citation></Reference><Reference><Citation>OMS.  Supplement to the WHO Polio Laboratory Manual. An alternative test algorithm for poliovirus isolation and characterization.   https://polioeradication.org/wp-content/uploads/2017/05/NewAlgorithmForPoliovirusIsolationSupplement1.pdf, 2019, Consulté le 13 mai 2020, 10.</Citation></Reference><Reference><Citation>Sylla K, Sow MS, Diallo MOS, Sy MM, Sako FB, Traoré FA, Bah I, Cissé MO, Sow DC, Baldé MS, Diallo AM. Paralysies flasques aiguës dues à des poliovirus: bilan de 11 années de surveillance en Guinée (2005-2015) Bull Soc Pathol Exot. 2020;113(1):35–38. doi: 10.3166/bspe-2020-0116.</Citation><ArticleIdList><ArticleId IdType="doi">10.3166/bspe-2020-0116</ArticleId><ArticleId IdType="pubmed">32881446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams AJ, Shaw J, Pallansch M, Kew O. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011 Apr 1;203(7):898–909. doi: 10.1093/infdis/jiq140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiq140</ArticleId><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>